Myriad showcases its pioneering research at the 2015 ASCO Annual Meeting

19 presentations will highlight Myriad's expanding portfolio of transformative diagnostic tests

2015-05-14

(Press-News.org) SALT LAKE CITY, Utah, May 13, 2015 - Myriad Genetics, Inc. (NASDAQ: MYGN) today announced it will present data from 19 clinical studies at the 2015 American Society of Clinical Oncology annual meeting to be held May 29 to June 2, 2015 in Chicago, Ill. Key podium presentations will highlight new prospective research programs with advanced companion diagnostic and molecular diagnostic tests aimed at revolutionizing how we treat and prevent cancers. Abstracts of the Company's presentations are available at: abstracts.asco.org. "Advances in personalized medicine will include selecting effective pharmaceuticals (companion diagnostics), preventing disease (hereditary caner tests) and in optimizing treatment decisions (prognostic tests). This meeting showcases our pioneering research in these three areas of personalized medicine. In companion diagnostics, the myChoice™ HRD test can transform the way we personalize treatment plans for ovarian and breast cancers today and many other cancers in the future," said Mark Capone, president Myriad Genetic Laboratories. "Another critical goal for personalized medicine is to prevent cancer. Our myRisk™ hereditary cancer panel test does just that by analyzing 25 genes associated with eight common hereditary cancers. Lastly, our prognostic tests demonstrate advances in optimizing treatments decisions in prostate cancer and lung cancer. As a pioneer in the field of personalized medicine, we remain firmly committed to scientific progress through outstanding research that can ultimately benefit patients." The list of key Myriad presentations follows.

1. COMPANION DIAGNOSTIC PRESENTATIONS myChoice HRD™: Podium Presentation Title: Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto.
Presenter: Gunter Von Minckwitz
Date: Monday, June 1, 4:12 - 4:24 p.m.
Location N Hall B1; Abstract: 1004

myChoice HRD: Poster Discussion Sessions Title: Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579).
Presenter: Virginia Kaklamani
Date: Saturday, May 30, 8:00 to 11:30 a.m.
Location: N Hall B1; Abstract: 1017, Poster: 131

Title: Combined homologous recombination deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple negative and/or BRCA1/2 mutation associated breast cancer.
Presenter: Melinda Telli
Date: Saturday, May 30, 8:00 to 11:30 a.m.
Location: N Hall B1; Abstract: 1018, Poster: 132

myChoice HRD: Poster Sessions Title: Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.
Presenter: Kirsten Timms
Date: Saturday, May 30, 8:00 to 11:30 a.m.
Location: Abstract: 1091, Poster: 205

Title: Association of tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based therapy in breast cancer (BC) with therapy resistance.
Presenter: Anosheh Afghahi
Date: Saturday, May 30, 8:00 to 11:30 a.m.
Location: Abstract: 1094, Poster: 208

Title: Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC).
Presenter: Jai Patel
Date: Saturday, May 30, 1:15 to 4:45 p.m.
Location: Abstract: 5534, Poster: 92

Title: Use of homologous recombination deficiency (HRD) score to enriche for niraparib sensitive high grade ovarian tumors.
Presenter: Keith Wilcoxen
Date: Saturday, May 30, 1:15 to 4:45 p.m.
Location: Abstract: 5532, Poster: 90

Title: Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC).
Presenter: Robert Brown
Date: Saturday, May 30, 1:15 to 4:45 p.m.
Location: Abstract: 5576, Poster: 134

BRACAnalysis CDx™: Poster Session

Title: A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.
Presenter: Stephanie Lheureux
Date: Saturday, May 30, 1:15 to 4:45 p.m.
Location: Abstract: TPS5613, Poster: 167a

2. HEREDITARY CANCER PRESENTATIONS myRisk™ Hereditary Cancer: Podium Presentation Title: Predisposing germline mutations in high grade ER+HER2- breast cancer (BC) patients diagnosed END

ELSE PRESS RELEASES FROM THIS DATE:

Economic burden of cancer extends into survivorship

2015-05-14

A new study finds the economic burden of cancer extends beyond diagnosis and treatment, and concludes that cancer survivors face thousands of dollars of excess medical expenses every year as well as excess employment disability and loss of production at work. The study abstract is being presented at the upcoming ASCO Annual Meeting and was released online today. Researchers led by Zhiyuan "Jason" Zheng examined the economic burden among survivors of the three most prevalent cancers (colorectal, female breast, and prostate) in nonelderly and elderly populations in the ...

Medical marijuana pill may not be effective in treating behavioral symptoms of dementia

2015-05-13

MINNEAPOLIS - A new study suggests that medical marijuana pills may not help treat behavioral symptoms of dementia, such as aggression, pacing and wandering. The research is published in the May 13, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology. However, researchers did find that the drug dosage used in the clinical trial was safe and well-tolerated. "Our study results are valuable since any firm evidence of the effectiveness and safety of medical marijuana in this disease area is scarce," said study author Geke A.H. van ...

Long-term depression may double stroke risk despite treatment

2015-05-13

DALLAS, May 13, 2015 -- Persistent depression may double the risk of stroke in adults over 50 -- and stroke risk remains higher even after symptoms of depression go away, according to research in the Journal of the American Heart Association. "Our findings suggest that depression may increase stroke risk over the long term," said Paola Gilsanz, Sc.D., study lead author and ?Yerby Postdoctoral Research Fellow at Harvard University's T.H. Chan School of Public Health in Boston, Mass. Researchers used data from 16,178 participants (ages 50 and older) who had been interviewed ...

Long-term depression may double stroke risk for middle-aged adults

2015-05-13

Boston, MA -- Adults over 50 who have persistent symptoms of depression may have twice the risk of stroke as those who do not, according to a new study led by researchers at Harvard T.H. Chan School of Public Health. Researchers found that stroke risk remains higher even after symptoms of depression go away, particularly for women. The study will be published online May 13, 2015 in the Journal of the American Heart Association. "This is the first study evaluating how changes in depressive symptoms predict changes in stroke risk," said lead author Paola Gilsanz, Yerby ...

A SMARTer approach to stroke care

2015-05-13

Time is critical when it comes to stroke, and early treatment is associated with better outcomes. According to the Screening with MRI for Accurate and Rapid stroke Treatment (SMART) study, small changes in quality improvement procedures enabled clinicians to use MRI scans to diagnose stroke patients before giving acute treatment, within 60 minutes of hospital arrival. MRI scans provide detailed images but take longer to complete than CT scans, which are commonly used in most centers. The findings, published in Neurology, were supported in part by the National Institutes ...

TGen study matches infant stiff-joint syndromes to possible genetic origins

2015-05-13

PHOENIX, Ariz. -- May 13, 2015 -- A study led by the Translational Genomics Research Institute (TGen) has for the first time matched dozens of infantile diseases and syndromes involving muscle weakness and stiff joints to their likely genetic origins. The study, in association with the University of British Columbia and BC Children's Hospital Vancouver, was published this month (May) in the American Journal of Medical Genetics. The study's goal is to better enable physicians and geneticists to advance new treatments that might help these children. "It's amazing to us ...

Saving critical time diagnosing stroke patients with MRI by borrowing 'lean' principles

2015-05-13

Washington, D.C., May 13, 2015 -- Using efficiency principles borrowed from "lean" manufacturing processes, two Washington-area hospitals have gotten a life-saving drug to stroke patients significantly quicker, while also obtaining better diagnostic information using MRI. That's according to a new study published online ahead of print in the May 13 issue of Neurology®, the medical journal of the American Academy of Neurology. National benchmarks call for getting stroke patients from the door of the emergency room to injection with the clot-busting drug known as ...

UM study uncovers why songbirds vary in time devoted to warming eggs

2015-05-13

MISSOULA -- The amount of time and effort songbirds spend warming their eggs directly correlates to their own survival probability and that of their eggs, according to a study by University of Montana researchers that will appear in an upcoming issue of The American Naturalist. The amount of care parents provide their young varies greatly across the animal kingdom, particularly among songbird species, who spend anywhere from 20 percent to nearly 100 percent of daylight hours warming eggs in their nests. A team of researchers led by Thomas Martin, senior scientist and ...

Vitamin D levels predict survival chances for sick cats, study finds

2015-05-13

Cats may hold vital clues about the health benefits of vitamin D, a study suggests. Researchers found that higher levels of vitamin D are linked to better survival chances for hospitalised pet cats. Cats could prove useful for investigating the complex link between vitamin D and a range of health problems that also affect people, the researchers say. The findings may also help vets to give owners better advice about their pets' prognosis, according to researchers at the University of Edinburgh's Royal (Dick) School of Veterinary Studies. Researchers examined blood ...

Burmese long-tailed macaque stone-tool use catalogued

2015-05-13

Eighty percent of a population of Burmese long-tailed macaques on an island in southern Thailand use stone and shell tools to crack open seafood, and do so using 17 different action patterns, according to a study published May 13, 2015 in the open-access journal PLOS ONE by Amanda Tan from Nanyang Technological University, Singapore, and colleagues, under an 8 year field project led by Michael D Gumert, also from NTU. The authors of the study explored variation in how Burmese long-tailed macaques used percussive stone and shell tools to hammer coastal foods on Piak Nam ...

Why Some Bacteria Survive Antibiotics and How to Stop Them - New study reveals that bacteria can survive antibiotic treatment through two fundamentally different “shutdown modes”

Myriad showcases its pioneering research at the 2015 ASCO Annual Meeting

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: